Biomarker and Tumor Responses of Oral Cavity Squamous Cell Carcinoma to Trametinib: A Phase II Neoadjuvant Window of Opportunity Clinical Trial

PURPOSE: Ras/MEK/ERK pathway activation is common in oral cavity squamous cell carcinoma (OCSCC). We performed a neoadjuvant (pre-operative) trial to determine biomarker and tumor response of OCSCC to MEK inhibition with trametinib. PATIENTS AND METHODS: Patients with Stage II–IV OCSCC received tram...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Clin Cancer Res
Главные авторы: Uppaluri, Ravindra, Winkler, Ashley E., Lin, Tianxiang, Law, Jonathan H., Haughey, Bruce H., Nussenbaum, Brian, Paniello, Randal C., Rich, Jason T., Diaz, Jason A., Michel, Loren P., Wildes, Tanya M., Dunn, Gavin P., Zolkind, Paul, Kallogjeri, Dorina, Piccirillo, Jay F., Dehdashti, Farrokh, Siegel, Barry A., Chernock, Rebecca D., Lewis, James S., Adkins, Douglas R.
Формат: Artigo
Язык:Inglês
Опубликовано: 2016
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5509449/
https://ncbi.nlm.nih.gov/pubmed/28151720
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-1469
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы